Biotech firm Arcellx's Q2 revenue misses estimates

Arcellx

07/08/2025 21:09

Overview

Arcellx Q2 revenue drops and misses analyst expectations, per LSEG data

Adjusted EPS for Q2 beats consensus, reflecting operational efficiency

Co ends Q2 with $538 mln cash, funding expected into 2028

Outlook

Arcellx plans 2026 launch of anito-cel in 160 US centers

Company expects cash reserves to fund operations into 2028

Arcellx to share longer-term iMMagine-1 data later in 2025

Company aims to meet physician supply expectations for anito-cel

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$7.55 mln
$13.60 mln (15 Analysts)
Q2 EPS
Beat
-$0.94
-$1.02 (17 Analysts)
Q2 Net Income
Beat
-$52.77 mln
-$56.30 mln (14 Analysts)
Q2 Operating Income
Beat
-$58.73 mln
-$61.20 mln (14 Analysts)
Q2 Pretax Profit
Beat
-$52.74 mln
-$55.20 mln (13 Analysts)
Q2 Operating Expenses
$66.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arcellx Inc is $113.50, about 37.7% above its August 6 closing price of $70.67

Press Release: ID:nBw2MgBKra

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)